Login to Your Account



Alexza Banking $40M Up Front in U.S. Adasuve Deal with Teva

By Jennifer Boggs
Managing Editor

Thursday, May 9, 2013

Shares of Alexza Pharmaceuticals Inc. jumped 29 percent Wednesday after the firm disclosed a U.S. commercialization partner for recently approved Adasuve, a version of antipsychotic drug loxapine delivered via the company's Staccato technology.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription